US Patent

US11969421 — Bupropion as a modulator of drug activity

Method of Use · Assigned to Antecip Bioventures II LLC · Expires 2034-11-05 · 8y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent describes methods of treating neurological or psychiatric diseases using a combination of bupropion and dextromethorphan.

USPTO Abstract

Disclosed herein are methods of treating neurological or psychiatric diseases or disorders using a combination of bupropion and dextromethorphan. Related compositions and dosage forms are also described.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3419`	—

Patent Metadata

Patent number: US11969421
Jurisdiction: US
Classification: Method of Use
Expires: 2034-11-05
Drug substance claim: No
Drug product claim: No
Assignee: Antecip Bioventures II LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.